NeuroNews’ top 10 most popular stories of May 2024


Global conference coverage piqued NeuroNews readers’ interest through the month of May—initially with discussions at the Charing Cross (CX) International Symposium (23–25 April, London, UK) and, later, thanks to new trial data presented at this year’s European Stroke Organisation Conference (ESOC; 15–17 May, Basel, Switzerland). Updates regarding novel neurovascular devices, including robotic stroke treatments and the latest aspiration catheter technologies, also feature.

1. First European PERFORMANCE II release highlights durability of carotid stenting in high-risk patients

The recent, first-time European presentation of the PERFORMANCE II trial’s findings—delivered by Ralf Langhoff (Sankt Gertrauden-Krankenhaus, Berlin, Germany) at the 2024 CX International Symposium—led delegates to discuss the role of stenting in carotid artery disease treatment, and how this has evolved in light of newer technologies.

2. Route 92 announces US FDA 510(k) clearance for FreeClimb 54 reperfusion system

Route 92 Medical has announced receipt of US Food and Drug Administration (FDA) 510(k) clearance for the FreeClimb 54 reperfusion system, comprised of the FreeClimb 54 aspiration catheter paired with a Tenzing 5 delivery catheter.

3. XCath successfully performs first public telerobotic mechanical thrombectomy demonstration

XCath has announced the successful completion of a “first-of-its-kind” live telerobotic trial for stroke treatment, which took place between Abu Dhabi, United Arab Emirates (UAE) and Seoul, South Korea at Abu Dhabi Global Healthcare Week (ADGHW; 13–15 May, Abu Dhabi, UAE).

4. Rapid Medical completes successful stroke procedures with “world’s first” robotic thrombectomy device

Rapid Medical has announced what it claims is the first successful robotic thrombectomy, in Medellín, Colombia. Two patients were treated with the robotic Tigertriever—an endovascular thrombectomy device that adapts autonomously to the patient’s anatomy.

5. ARISE I recommends multidisciplinary approach to managing brain aneurysms, chronic SDHs and AVMs

Three papers published in the journal Stroke have highlighted multidisciplinary care and global, collaborative efforts as “paramount” in the management of intracranial aneurysms, chronic subdural haematomas (cSDHs), and brain arteriovenous malformations (AVMs). These recommendations were led by the Aneurysm/AVM/cSDH Roundtable Discussion with Industry and Stroke Experts (ARISE) group, which facilitates conversations between academia, industry, and regulators, and ultimately intends to optimise acute stroke care.

6. Penumbra launches Midway intermediate catheters and expands European stroke portfolio

Penumbra recently announced the launch of its Midway 43 and Midway 62 delivery catheters, which are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature. This news came on the same day that the company also announced the CE-mark certification and European launch of three of its reperfusion catheters for acute ischaemic stroke: Red 43, Red 72 with Sendit technology, and Red 78.

7. Cerevasc secures US$70 million financing following US FDA approval of STRIDE study

Cerevasc announced recently that it has successfully completed the initial closing of a US$70 million Series B financing, which was jointly led by Bain Capital Life Sciences and existing investor Perceptive Xontogeny Venture Fund (PXV), with additional participation from other existing investors.

8. Evidence weak but craniectomy may be superior to medical therapy in severe, deep ICH

Despite the study very narrowly failing to meet its prespecified primary endpoint, the SWITCH randomised controlled trial has shown a substantial treatment effect with decompressive craniectomy procedures in people with severe, deep supratentorial intracranial haemorrhage (ICH). These findings were presented for the first time at ESOC 2024 by Urs Fischer (University Hospital of Bern, Bern, Switzerland) and Jürgen Beck (University Hospital Freiburg, Freiburg, Germany).

9. Ceretrieve announces successful results in FIH study of stroke aspiration catheter

Ceretrieve has announced the successful results of the company’s multicentre, single-arm study, showcasing the capabilities of its “state-of-the-art” aspiration catheter in stroke treatment.

10. Large-core ischaemic stroke patients with severe hypodensity may benefit less from thrombectomy

While the randomised controlled SELECT2 trial initially found that patients with large-core ischaemic stroke receive a greater benefit from thrombectomy compared to medical management, a secondary analysis of data from the study has now shown that the benefits of thrombectomy are less certain in patients with severe hypodensity of ≥26ml within their ischaemic lesions—and the likelihood of a hemicraniectomy being required is increased in these patients as well.


Please enter your comment!
Please enter your name here